Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
381 stopped studies mapped to Malignant Kidney Neoplasm and descendants · 86% state a reason
Over the 381 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01482949 | A Rollover Protocol for Subjects Previously Treated With AGS-003 | Phase 2 | terminated | Dec 1, 2011 | Argos Therapeutics | Lack of efficacy | Efficacy / futility |
| NCT02626754 | A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell… | Phase 2 | terminated | Dec 10, 2015 | vghtpe user | In most sites had difficult to recruitting subjects. | Enrollment / accrual |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation… | Phase 2 | withdrawn | May 11, 2017 | Medical University of South Carolina | This study is withdrawn due to feasibility issues. | Other (stated, no rule matched) |
| NCT01582672 | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of…(ADAPT) | Phase 3 | terminated | Apr 23, 2012 | Argos Therapeutics | Lack of efficacy | Efficacy / futility |
| NCT02511275 | Nephrotoxicity Associated to Parenchymal Clamping During Partial Nephrectomy Using a…(NECPAR) | N/A | terminated | Jul 30, 2015 | Centre Hospitalier Universitaire de Saint Etienne | this type of surgery is now performed with a surgical robot that no longer allows the realization… | Other (stated, no rule matched) |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | terminated | Sep 7, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT02747173 | Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and…(METHEOS) | — | terminated | Apr 21, 2016 | Spanish Oncology Genito-Urinary Group | not stated | Not stated |
| NCT03456401 | Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)(TOKIO) | Phase 2 | terminated | Mar 7, 2018 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | availability of new and more promising therapeutic agents than expected in the experimentation in… | Other (stated, no rule matched) |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma… | Phase 2 | withdrawn | Nov 11, 2016 | University of Kansas Medical Center | Due to competing trials. Stopped before IRB approval. | Other (stated, no rule matched) |
| NCT01931462 | Microwave Coagulation in Partial Nephrectomy Protocol | N/A | terminated | Aug 29, 2013 | University of Wisconsin, Madison | Slow enrollment | Enrollment / accrual |
| NCT02338570 | Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With…(ORCHIDEE) | Phase 4 | terminated | Jan 14, 2015 | Mario Negri Institute for Pharmacological Research | Stopped on November 16th 2016, because of recruitment failure. | Enrollment / accrual |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | Phase 1 | terminated | Nov 13, 2009 | Masonic Cancer Center, University of Minnesota | PI left institution. | Investigator |
| NCT01762592 | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With… | Phase 3 | withdrawn | Jan 7, 2013 | Heidelberg Pharma AG | new sponsor | Other (stated, no rule matched) |
| NCT02370342 | Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small… | N/A | withdrawn | Feb 24, 2015 | University of Southern California | No funding | Funding |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone… | Phase 1 / Phase 2 | withdrawn | Oct 9, 2008 | Masonic Cancer Center, University of Minnesota | No patient accrual. | Enrollment / accrual |
| NCT00623077 | MT2004-30: Tomotherapy for Solid Tumors | Phase 1 | terminated | Feb 25, 2008 | Masonic Cancer Center, University of Minnesota | Replaced by another study | Other (stated, no rule matched) |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | Phase 1 | terminated | May 2, 2003 | Masonic Cancer Center, University of Minnesota | Withdrawn due to slow accrual | Enrollment / accrual |
| NCT02122003 | Second Line Sorafenib After Pazopanib in Patients With RCC(SOAP) | Phase 2 | terminated | Apr 24, 2014 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | availability of new and more promising therapeutic agents than expected in the experimentation in… | Other (stated, no rule matched) |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | Phase 1 | terminated | Sep 12, 2005 | GlaxoSmithKline | not stated | Not stated |
| NCT02138578 | Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal… | N/A | terminated | May 14, 2014 | University of Michigan Rogel Cancer Center | Due to changes in scanning procedure, and infeasible biopsy and baseline imaging, the trial closed… | Enrollment / accrual |
| NCT01492192 | RGD-PET-CT in Cancer Angiogenesis | Phase 2 | terminated | Dec 14, 2011 | Oxford University Hospitals NHS Trust | not stated | Not stated |
| NCT01784978 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m…(SUNRISES) | Phase 2 | terminated | Feb 6, 2013 | Associació per a la Recerca Oncologica, Spain | Lack of recruitment | Enrollment / accrual |
| NCT00003520 | Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT02089802 | Optimizing Pazopanib Exposure in RCC Patients(OPERA) | Phase 2 | terminated | Mar 18, 2014 | Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. | Early termination due to lack of recruitment | Enrollment / accrual |
| NCT00089778 | Vaccine Treatment of Kidney Cancer | Phase 2 | terminated | Aug 13, 2004 | National Cancer Institute (NCI) | fewer tumors than expected expressed FGF-5, led to end of accrual to cohorts A\&B | Enrollment / accrual |
| NCT01598038 | Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal… | N/A | terminated | May 15, 2012 | Centre Francois Baclesse | not stated | Not stated |
| NCT02928263 | Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma… | — | withdrawn | Oct 10, 2016 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of… | Phase 1 / Phase 2 | withdrawn | Aug 6, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal…(5-AZ) | Phase 1 / Phase 2 | terminated | Jul 8, 2009 | University of Kansas Medical Center | not stated | Not stated |
| NCT01599832 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib… | N/A | terminated | May 16, 2012 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT00899860 | Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone… | — | terminated | May 12, 2009 | Wake Forest University Health Sciences | PI left institution | Investigator |
| NCT00651482 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001… | Phase 2 | terminated | Apr 2, 2008 | Sandy Srinivas | slow accrual | Enrollment / accrual |
| NCT02071641 | Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Feb 26, 2014 | Amsterdam UMC, location VUmc | not stated | Not stated |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem… | Phase 2 | terminated | Jun 17, 2008 | University of Arizona | Pentostatin/alemtuzumab regimen had greater risk of graft failure. | Other (stated, no rule matched) |
| NCT00467077 | Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic… | Phase 2 | terminated | Apr 27, 2007 | California Cancer Consortium | Protocol was closed due to slow accrual. | Enrollment / accrual |
| NCT01943188 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With… | Phase 1 | terminated | Sep 16, 2013 | Stanford University | not stated | Not stated |
| NCT01264341 | Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell… | Phase 2 | terminated | Dec 21, 2010 | Hellenic Cooperative Oncology Group | Based on the developments in the treatment of recurrent metastatic renal cancer, the study… | Other (stated, no rule matched) |
| NCT01441765 | PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | Phase 2 | terminated | Sep 28, 2011 | Beth Israel Deaconess Medical Center | Funding | Funding |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | Phase 2 | terminated | Oct 30, 2007 | National Institutes of Health Clinical Center (CC) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT00672178 | Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic,… | Phase 1 / Phase 2 | terminated | May 6, 2008 | Duke University | Slow accrual | Enrollment / accrual |
| NCT01712685 | Imaging Studies of Kidney Cancer Using 18F-VM4-037 | Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | Study was closed to accrual because imaging agent was no longer available. | Enrollment / accrual |
| NCT02410174 | To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma… | Phase 1 | terminated | Apr 7, 2015 | Beth Israel Medical Center | Poor Accural | Other (stated, no rule matched) |
| NCT01144169 | Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | Phase 1 | terminated | Jun 15, 2010 | University of Pittsburgh | barriers to accrual: delay until surgery and additional pre-operative visits | Enrollment / accrual |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | Phase 3 | withdrawn | May 23, 2003 | Genentech, Inc. | No patients were enrolled, study cancelled before start | Enrollment / accrual |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT00318110 | Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Apr 26, 2006 | Center for International Blood and Marrow Transplant Research | Unable to meet subject enrollment goal. | Enrollment / accrual |
| NCT01336231 | Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in…(COG-ANGIO) | — | terminated | Apr 15, 2011 | Centre Francois Baclesse | lack of recruitment | Enrollment / accrual |
| NCT01326390 | Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular… | — | terminated | Mar 30, 2011 | Stanford University | not stated | Not stated |
| NCT00556205 | Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | Phase 2 | withdrawn | Nov 9, 2007 | Massachusetts General Hospital | Toxicity of combination from other trials | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 27, 2018source: clinicaltrials